Advertisement
(Photo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO )
"We are very pleased to have been issued this patent in China and toextend our protection in another important market," stated Tim Hansen, IMDSChief Executive Officer. "With this patent comes additional hope that breastcancer may someday be imaged and treated with light-activated compounds. Ourcurrent proprietary CT Laser Mammography System (CTLM(R)) is uniquely capablein these applications."
Advertisement
The Chinese patent, ZL 99 8 16608.1, joins the Australian patent 775069,issued July 2004; European patent EP01181511, issued June 2005; Hong Kongpatent HK1043480, issued January 2006; and German patent DE69925869 issued May2006. The patents, along with a previously issued Canadian patent, areequivalents of US patent 5,952,644. They protect the concept of imaging andactivating a photodynamic therapy agent in an optical CT scanner, a combineddiagnostic and therapeutic system.
This is the second patent issued to IMDS in China.
About Imaging Diagnostic Systems, Inc.
Imaging Diagnostic Systems, Inc. has developed a revolutionary new imagingdevice to aid in the detection and management of breast cancer. The CTLM(R)system is a breast imaging system that utilizes patented continuous wave lasertechnology and computer algorithms to create 3-D images of the breast. Theprocedure is non-invasive, painless, and does not expose the patient toionizing radiation or painful breast compression. CT Laser Mammography(CTLM(R)) is designed to be used in conjunction with mammography. It revealsinformation about blood distribution in the breast and may visualize theprocess of angiogenesis, which usually accompanies tumor growth.
Imaging Diagnostic Systems is currently collecting data from clinicalsites for the future filing of an FDA Premarket Approval (PMA) for theComputed Tomography Laser Mammography (CTLM(R)) system to be used as anadjunct to mammography. The FDA has determined that the Company's clinicalstudy is a non-significant risk (NSR) investigational device study under812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR812). The CTLM system is limited by United States Federal Law toinvestigational use only in the United States. The CTLM system has receivedother registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO9001:2000, ISO 13485:2003 and FDA export certification.
For more information, visit our website: www.imds.com
As contemplated by the provisions of the Safe Harbor section of thePrivate Securities Litigation Reform Act of 1995, this news release maycontain forward-looking statements pertaining to future, anticipated, orprojected plans, performances and developments, as well as other statementsrelating to future operations. All such forward-looking statements arenecessarily only estimates or predictions of future results or events andthere can be no assurance that actual results or events will not materiallydiffer from expectations. Further information on potential factors that couldaffect Imaging Diagnostic Systems, Inc., is included in the Company's filingswith the Securities and Exchange Commission. We expressly disclaim any intentor obligation to update any forward-looking statements.Investor Relations: Rick Lutz 404-261-1196 [email protected] Media Contact: Elizabeth Williams (954) 581-9800 [email protected]
SOURCE Imaging Diagnostic Systems, Inc.
